Lausanne, Switzerland – September 13, 2017 – Debiopharm Investment SA (Debiopharm – www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced that they have acquired a minority stake in Gammed AG of Switzerland, the holding company for Les Toises clinics. This investment will allow the company to pursue its development in the long term. The current management team of this family company will still hold a significant majority stake and will remain in place to continue to steer its progress.
The first Les Toises clinic was founded in 2009 by Dr Franziska Gamma Van Appelghem and her husband Jean-Marie Van Appelghem in Lausanne with a team of five therapists. Today they have over 150 employees and have treated more than 14,000 patients, making them a benchmark for psychotherapy and psychiatric care in French-speaking Switzerland.
The success of Les Toises is based on three fundamental strengths:
- The quality of the psychiatric care and outpatient psychotherapy offered
- Easy, rapid access
- Individual, personalised care programmes
Services are provided for all age groups: children, adolescents, adults and the elderly. Les Toises accepts all patients requiring treatment as outpatients, in its day centre, or in its emergency and crisis centre, where needed providing assistance with social welfare issues and support to family members acting as carers.
Treatment is offered in over 20 languages in particular through the use of telemedicine.
This innovative model is supported by a first-class internal organisation and state-of-the-art IT tools.
The excellence of the care provided at Les Toises has allowed the company to qualify as a postgraduate training establishment for psychiatry and psychotherapy, making it even more attractive for healthcare professionals.
Maintaining its growth trend, the company opened a second site in the canton of Vaud, at Yverdon, in late summer 2016. This year, it is continuing to expand by moving into two new cantons: Fribourg in May 2017 and Valais, in the town of Sion (expected to open in early September 2017).
This trend will be sustained over the next few years, putting Les Toises on a national scale. Debiopharm will work alongside the founders to reinforce this strong growth.
The acquisition of this stake reflects Debiopharm’s commitment to the personal care services sector. As Thierry Mauvernay, Delegate of the Board of Debiopharm Group, emphasised: “This investment ties in well with our Group’s desire to help improve the patient experience”.
About Debiopharm Investment SA
Debiopharm Investment SA pursues its mission to preserve, diversify and support the sustainable growth of Debiopharm Group™, a biopharmaceutical development company based in Lausanne (Switzerland), through a comprehensive investment strategy centered on three areas of activity: Finance (portfolio management, currency hedging), Real Estate (residential and commercial) and Private Equity.
The Private Equity team focuses primarily on investment diversification, managing a portfolio of funds and of direct equity investments, as minority shareholder, in the capital of pioneering start-ups as well as small and medium-sized European companies.
Our entrepreneurial culture, as well as our willingness and capacity to act as long-term partners of the teams with which we invest, are the established pillars of our commitment.
For more information, please visit www.debiopharm.com
Debiopharm Investment SA Contact
Private Equity Manager
Tel: +41 (0)21 321 01 11